Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir

Authors: Rivas, P¹; Górgolas, M²; García-Delgado, R³; Díaz-Curiel, M⁴; Goyenechea, A²; Fernández-Guerrero, ML²

Source: HIV Medicine, Volume 9, Number 2, February 2008 , pp. 89-95(7)

Publisher: Wiley-Blackwell

Abstract:

Objectives

The aim of the study was to determine the factors that may contribute to decreases in bone mineral density (BMD) in patients with AIDS. Methods

This was a prospective, non-randomized study. Dual X-ray absorptiometry (DXA) was used to determine the BMD of the lumbar spine, femoral neck and distal radius in treatment-naïve HIV-infected male patients with AIDS before and after 1 year of treatment with zidovudine (ZDV)/lamivudine (3TC) plus abacavir (ABC) or lopinavir/ritonavir (LPV/r). Results

Basal DXA was performed in 50 patients with CD4 counts <200 cells/μL and/or any AIDS-defining condition. Thirty-two patients completed 1 year with full adherence (17 on ABC and 15 on LPV/r) and a second DXA was then performed. At baseline, 19% had osteopenia at the lumbar spine and 19% at the femoral neck. Low body weight was related to low BMD. After 48 weeks, BMD loss was significant at the three locations. The percentage of BMD loss at the femoral neck tended to be greater in the lopinavir group (5.3 vs. 3.2%, P=0.058). The differences became significant at the lumbar spine (5.7 vs. 2.7%, P=0.044). In the multivariate analysis, the treatment with LPV/r remained associated with bone loss at the lumbar spine. Conclusions

Osteopenia is frequent in treatment-naïve HIV-infected men with AIDS. Bone loss is higher with LPV/r-based regimens compared with triple nucleoside reverse transcriptase inhibitors.

Keywords: adverse effects; bones; highly active antiretroviral therapy; HIV; osteoporosis

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1468-1293.2007.00525.x

Affiliations: 1: Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain, 2: Division of Infectious Diseases, Fundación Jiménez Díaz, Madrid, Spain, 3: Service of Immunology, Fundación Jiménez Díaz, Madrid, Spain, and 4: Service of Internal Medicine, Fundación Jiménez Díaz, Madrid, Spain

Publication date: 2008-02-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Allergy & Immunology ,  Internal Medicine ,  Pediatrics
• By this author: Rivas, P ;  Górgolas, M ;  García-Delgado, R ;  Díaz-Curiel, M ;  Goyenechea, A ;  Fernández-Guerrero, ML

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers